AstraZeneca plc: Strategic Management and Sustainability Report

This report provides a comprehensive analysis of AstraZeneca plc, a leading British multinational pharmaceutical company, focusing on its strategic management and sustainability practices over the past five years. It identifies key business strategies, including late-stage pipeline transformation, immuno-oncology portfolio development, and market expansion, examining how these strategies have evolved and been pursued. The report also evaluates AstraZeneca's resources and capabilities, encompassing physical, human, financial, and intellectual capital, as well as dynamic capabilities like innovation and development, and assesses the strategic fit between these resources and the company's business strategies. Furthermore, it explores the company's environmental sustainability initiatives, considering theories and approaches to enhance its competitive position. The analysis includes PESTEL and SWOT analyses to provide a holistic view of the company's external and internal environments, offering valuable insights into AstraZeneca's strategic direction and performance.

Strategic Management and
Sustainability

Table of Contents
Introduction....................................................................................................................................1
MAIN BODY..................................................................................................................................1
Key business strategies within last five years and find work to discuss strategy changed and
pursued.........................................................................................................................................1
Resource and capabilities of company over the last five years...................................................1
Revelation of how company can implement environmental sustainability and they are thinking
to become more competitive........................................................................................................1
CONCLUSION..............................................................................................................................1
REFERENCE.................................................................................................................................1

Introduction
A sustainable management is the intersection of the business and sustainability. It is the practise
of managing organisational impact on the three bottom lines that covers profit, people and planet
So that all three can proposer in the future.
This report will cover the study of AstraZeneca plc Which is British British multinational
pharmaceutical company who are having headquarters in Cambridge England. they are having
huge portfolio of product for some of the major diseases like infections, Oncology, Respiratory
etc. It is perhaps best known for there involvement in developing covered vaccine called Oxford-
AstraZeneca.
This report will identify key business strategies of the AstraZeneca plc within past five years by
using the framework to discuss why this strategy was pursued or changed. It will also identify
the evidence sources and capability of AstraZeneca plc over the past five years and Analysation
of what extent the company has aligned there capability and sources to their business strategies.
In the end of this report will conclude environmental sustainability, theories and way of thinking
to become more competitive.

MAIN BODY
Key business strategies within last five years and find work to discuss strategy changed and
pursued
AstraZeneca Is one of the leading pharmaceutical company who are having huge reputation in
all over the world, in between last five years they have implemented various strategies that
helped them to take competitive advantages some of them may changed with the time and some
of their pursued newly. late stage pipeline transformed well ahead of plan through the increase
research and productivity, accelerate the target business development and accelerate
programmes, company has come up with the 14 potential new medicines that across the base 3 or
registration, potential for 16 to 14 submissions an 18 to 10 approvals company get in year 2015
to 16 (Baumgartner, and Rauter., 2017.
). Industry leading immuno- oncology Portfolio with the combination of 13 trials that undertake
and 16 are planned by the company, acquisitions help to define and accelerate the further clinical
programmes through the prognostic biomarker testing and precise predictive test.
The five current growth of the organisation on the platform are emergency markets, Brillianta,
repertory, donates. They have also opened the new accounts for more than half of their global
revenue Ray showing their growth within the market.! their business is taking the shape Neil
evolving to become more profitable and sustainable on the global level, biologics account for
new nearly 50% of pipeline, Increasing the probability of success an enhancing companies
durability that is along with the growing focus on portfolio balance on the devices of primary and
specialty care boost probability,. Oncology Is the most important therapeutic Area in which
AstraZeneca company has the good knowledge and deep rooted heritage. It will potentially
transformational for the future of company and there becoming the 6th fastest growing platform
in all over the world. their vision is to help patients and the treatment of cancer. By 2020 their
aim is to bring 6 new cancer medicine for the patients so they can recover more faster and feel
better by taking the medicines.
The positive CHMP Opinion get for the lynparza, In the EUEuropean and we they anticipate
European and US approvals in the first quarter of 2015 with further studies ongoing and gastric,
breast and pancreatic Cancers and early stage activities of the cancer.
PESTEL Analysis of AstraZeneca

Political
Political vectors has huge what are the impact on the AstraZeneca, they get support from the UK
government UK government to create medicines and during the COVID-19 government help in
funding so AstraZeneca develop the very medicines that can had to recover from the COVID 19
impact.
Economical
Economical factor or economical crises impact whole business of the AstraZeneca. Before the
COVID-19 company was focused toward the other disease and medicines but after the covert
crisis they put years in creating or developing the covid vaccine (Gachuhi and Awuor., 2019).
The crisis also impact their probability becausr there mainly focused toward the developing
vaccine rather than distributing the other disease medicines to the countries.
Social
AstraZeneca Develop their medicines and other products with the proper research and
development that helps to create a good image in customers mind and people are happy with the
medicines provided by the AstraZeneca and mostly health professional recommend and use the
medicines made by the AstraZeneca. Many people who are suffering from the cancer disease
another disease are able to use medicines developed by AstraZeneca
Technological
technology has various use and having huge competitive advantages for the company.
Companies using the technology equipment and developing the medicines I’m doing the research
and development that is helping them to come up with the better result outcome for the treatment
of diseases so they can forward the benefits to the general public. researches and development
facilities located in seven various countries among all of them six are present in UK, they are
having manufacturing sites around 30 based on 20 countries Anne nine of them are in United
Kingdom. the dynamic capability of the company is their location in the UK. For example
companies European business service offices are located in northwest Chorlton- Cum hardy
Which is near be close to the centre of Manchester
Environmental

Regulations and standards of environmental both national and local level often the environmental
policies at the national and local level can be different. This can help the AstraZeneca In
numerous decisions such as plant location, pricing strategy and product development.
Legal
AstraZeneca is the authorised and permitted pharmaceutical company and they develop all the
medicines with years of research and development and also approved the all test and phase That I
need it for the approval of medicine.
Resource and capabilities of company over the last five years
AstraZeneca One of the leading pharmaceutical company with various resources and capability
that is help them to take competitive advantages within the past five years. some of the physical
resources that they have developed within several countries (Calabrese., and et.al., 2019).
Manufacturing plant s
They have around 30 sides that are manufacturing within the 29 countries an along with the
several are in United Kingdom. This is showing how widely they have expanded their business
and manufacturing medicines all around the world
Human capital
employees were working within the AstraZeneca Skillful and and they are having higher
knowledge. There are various number of scientists who are working for the company and
financial capital this can be accessed through access to funds that can include the farm's owner
revenue and borrowing power. this company generate around 11.8 pound billion and produce
operating profit of £2.6 billion.
Intellectual Capital
Intellectual capitalise that carried out goodwill, reputation and corporate image as well through
the world and UK particular medicines that are made by the AstraZeneca that are recognised
Bragg as world class or world leading treatments. they are also having good relation with their
suppliers Anne stakeholder that is also helping them too create a good imagine outside world and
helping them to grow affectively.

Dynamic capability
Innovation & development
This company manufacture and sell the various drugs an innovative therapy that helps to combat
various medical conditions that include cancer diabetes etc. Research and development carried
out 11 researches and development facalities located in seven various countries among all of
them six are present in UK, they are having manufacturing sites around 30 based on 20 countries
Anne nine of them are in United Kingdom. the dynamic capability of the company is their
location in the UK. For example companies European business service offices are located in
northwest Chorlton- Cum hardy Which is near be close to the centre of Manchester
On the other side AstraZeneca company also spend on stages of development of each medicine
that can cost around £500 million in Additionally to the Az continue research and development
treatments for the serious this is this inhuman. The HR sales and marketing of the company
located at the same faculty nearby the satellite site (Sullivan, Thomas, and Rosano., 2018).
Strategic fit
The strategic Is helpful to express the degree in which company matches their capability and
resources with the appointees in external environment are there existing business strategy. this
company have good benefits of the strategic fit that can include the cost reduction due to the
economic of scales and transfer the skills and knowledge.
In the position of the AstraZeneca The business fit between the capability and resources to create
a opportunities and demand that address there some of the strategic needs that gives this strength
and competitive advantages to the company that also helps to explore the use of new
technologies or creates new market for the company.
On the other hand development of the different technology and product alternatives shows that
the company have used advanced technology any handing their research and development to
create a various products and medicines for the human welfare. Element of different business
plans and product profiles this has been generated good result and millions of among Which
spend on the research and development as describe and previous topics. AstraZeneca is the one
of the key growing company and helping UK economy to grow, this is characterised by the

recognition of knowledge and sources of competitiveness, the importance of technology,
researchers any nobody knowledge creation and the use of ITC to generate shares and apply
knowledge. disadvantages are with the couple of sponsorship with the different educational
programmes in colleges and schools to produce knowledge based company (Domingues., and
et.al., 2017). His company is the third best pharmaceutical and lead in the research and
development of medicines and they are having capability to successfully carried a wide range of
drugs and Medicine’s.
SWOT analyses of AstraZeneca
Strength
 AstraZeneca Is having strong research and development Advance with the board therapy
exposure to the company.
 Over the past five years company has been strong unreliable distribution network that
can able to reach the potential market and they can provide their medicines on time so
treatment can be provided to the patients and they can overcome from the disease.
 Yeah well authorised and 3rd best pharmaceutical company in the United Kingdom and
they are having good reputation in the market that allows them to sell their products all
over the world.
Weakness
 Discontinuation of product in the later stage of development most of the drugs company
was developing stuck in the 3rd our second stage and they were not able to developed.
 The marketing of the medicine’s sell by the AstraZeneca Left lots of desire. he went
through the product is very successful in terms of sales but the positioning an unique
selling proposition is not clearly dandified.
 Financial planning is not done properly an effective by the AstraZeneca. they can still use
the financial resources to develop more medicines and take competitive advantages
within the market.
Opportunities

 Company can reduce the development time of medicine’s if they collaborate with the
research and development team of the other companies that will help them to develop
medicine’s in less time and they were able to take competitive advantages.
 Globalisation can be a good opportunity for the AstraZeneca and it can help them to
develop new products medicines and drugs.
 Market agreement with the Company wising To capital on the AstraZeneca marketing
stands and providing growth in the process of company (Sroufe., 2017).
Threat
 Competition in the Pharmaceutical industry creating pressure on the AstraZeneca.
Recently covid vaccine creation Process also create pressure on the company because
many companies take participation and creating the vaccine.
 The new Mikaela Mick emergency in China India and competition in diverse Indian
competition in diverse rig ocean recognition markets.
Revelation of how company can implement environmental sustainability and they are thinking to
become more competitive.
It is necessary for the AstraZeneca Company to implement the environmental sustainability
and they should change the way of thinking so they can become more competitive in the industry
where they are operating their business. there are various opportunities that can be grabbed by
the company and they can show their presence and overtake the other competitors.
There are various natural resources that are used in developing the medicines for the
treatment, pharmaceutical companies test those medicines on the animals that is affecting the
environment. it is necessary for the AstraZeneca to be more environmentally sustainable and that
can possible if they help to save the natural resources and use some of the other resources that
can be replaced and they should not test on the animal before using the medicine in the market
(Stevens., and et.al., 2018). There are many other methods that can be used to see the
effectiveness of medicine's and company can use those strategies Toby sustainable and they can
create a good image in mind of community.
To become a more competitive within the market it is necessary for the company to
develop sustainable an environmental activities and they should change their thing too be more
competitive there are many other ways to be competitive in the market.

For the environmental sustainability AstraZeneca company can also run the programme
that will that can create awareness among the people about environmental issues. they can run
their own campaign that will help to aware people about the issue of global warming and many
other environmental issues that should be looked by the people so their support can be gained
and it will also help the company to create a good image in customers mind and they were able
to take competitive advantages within the market where they are operating their business and
they were able to show their presence in the market. it will also help them to get a support from
the government so they will be able to run their business smoothly ma have a good market
reputation and United Kingdom (Wijethilake., 2017). Regulations and standards of
environmental both national and local level often the environmental policies at the national and
local level can be different. This can help the AstraZeneca In numerous decisions such as plant
location, pricing strategy and product development.
CONCLUSION
As per the report has been identified key business strategies of the AstraZeneca plc
within past five years by using the framework to discuss why this strategy was pursued or
changed. It also has been discussed the evidence sources and capability of AstraZeneca plc over
the past five years and Analysation of what extent the company has aligned there capability and
sources to their business strategies. In the end of this report has been concluded environmental
sustainability, theories and way of thinking to become more competitive.

REFERENCE
Books and journals
Baumgartner, R. J. and Rauter, R., 2017. Strategic perspectives of corporate sustainability
management to develop a sustainable organization. Journal of Cleaner Productio. 140. pp.81-92.
Gachuhi, L. and Awuor, E., 2019. Strategic Management Practices and Sustainability of
SME’ s Agribusiness in Kenya: A Survey of Githunguri Sub County. Journal of
Agriculture. 3(1). pp.21-42.
Calabrese, A., and et.al., 2019. Integrating sustainability into strategic decision-making: A fuzzy
AHP method for the selection of relevant sustainability issues. Technological Forecasting and
Social Change. 139, pp.155-168.
Sullivan, K., Thomas, S. and Rosano, M., 2018. Using industrial ecology and strategic
management concepts to pursue the Sustainable Development Goals. Journal of Cleaner
ProduChang. 174. pp.237-246.
Domingues, A. R., and et.al., 2017. Sustainability reporting in public sector organisations:
Exploring the relation between the reporting process and organisational change management for
sustainability. Journal of environmental management. 192. pp.292-301.
Sroufe, R., 2017. Integration and organizational change towards sustainability. Journal of
Cleaner Production. 162. pp.315-329.

Stevens, J. R., and et.al., 2018. The rise of aquaculture by-products: Increasing food production,
value, and sustainability through strategic utilisation. Marine Policy. 90. pp.115-124.
Wijethilake, C., 2017. Proactive sustainability strategy and corporate sustainability performance:
The mediating effect of sustainability control systems. Journal of environmental management.
196. pp.569-582.